We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VAXIGRIP TETRA (Sanofi-Aventis Australia Pty Ltd)
Product name
VAXIGRIP TETRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
168 working days (255)
Active ingredients
Inactivated Quadrivalent Influenza Vaccine (Split Virion) influenza virus haemagglutinin
Registration type
NCE/NBE
Indication
VAXIGRIP TETRA (suspension for injection) is indicated for active immunisation of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.